This week on TWIRx, we head into NCPA 2026 with independent community pharmacy front and center — from artificial intelligence and consolidation to supply-chain economics and policy reform.
We start with the TWIRx Rumor Mill — Behind the Counter Intelligence, looking at three developing stories worth watching.
TWIRx RUMOR MILL — TOP 3
1. Another massive pharmacy transaction may be coming.
The owner of Walgreens Boots Alliance is reportedly nearing a deal to sell UK pharmacy giant Boots to the Weston family in a transaction valued at roughly $9 billion, including debt. The Weston interests already control Loblaw Companies and Shoppers Drug Mart in Canada. No final transaction has been announced, so this remains one to watch.
TWIRx Take: Pharmacy consolidation isn't slowing down. As major organizations continue reorganizing, buying, selling, and vertically integrating assets, what does that mean for independent pharmacy — and where does scale become too much scale?
2. Specialty pharmacy keeps getting bigger — and Cigna sees an enormous opportunity.
At its 2026 Investor Day, Cigna identified a specialty pharmacy and care-services market approaching $500 billion, with Accredo and its specialty operations positioned as major growth drivers.
TWIRx Take: Follow the money. Specialty drugs, rare disease, biologics, infusion and complex medication management continue to reshape pharmacy economics. The question for community pharmacy is: How much of this expanding market can independents capture?
3. AI is moving from pharmacy experiment to pharmacy infrastructure.
Just as NCPA prepares to make AI implementation one of the major topics at its 2026 Annual Convention, health-profession regulators are increasingly discussing governance and accountability surrounding AI. NCPA's programming includes real-world AI implementation and operational applications for community pharmacies.
TWIRx Take: The conversation is changing from "Should pharmacy use AI?" to "How do we use it responsibly, profitably and safely?"
And that takes us directly into our first featured conversation.
SEGMENT 1
John Boos, PharmD, MBA — HendrenAI
AI Meets Independent Community Pharmacy
Sponsored by HendrenAI and Independent Pharmacy Cooperative
NCPA 2026 officially opens October 3 in Kansas City, with independent pharmacy owners and innovators gathering to focus on practical ways to increase efficiency, expand services and strengthen pharmacy profitability. AI implementation is specifically among this year's featured topics.
In Part One of our conversation with John Boos, PharmD, MBA of HendrenAI, we set the stage for NCPA 2026 and examine what artificial intelligence can realistically do for independent pharmacy.
This isn't AI replacing the pharmacist.
It's AI giving pharmacists and their teams additional capacity.
As margins tighten and workload continues to increase, the pharmacies that intelligently automate routine work may be able to redirect valuable human time toward the things pharmacists do best: patients, clinical care, relationships and growing the business.
SEGMENT 2
Yvonne Dominguez — Independent Pharmacy Cooperative
IPC Acquires IntegralRx
Independent Pharmacy Cooperative recently announced its acquisition of IntegralRx, bringing together two organizations serving independent community pharmacies.
IntegralRx has supported thousands of pharmacies through purchasing opportunities, service and pharmacy relationships. IPC says the acquisition will expand access to products, services and resources designed to help pharmacy owners remain competitive and profitable.
We talk with Yvonne Dominguez about:
Why IPC made the acquisition
What IntegralRx brings to the cooperative
What changes — and what stays the same — for IntegralRx pharmacies
How scale can strengthen independent pharmacy purchasing power
Why independent pharmacies increasingly need collaboration without surrendering their independence
TWIRx Question: Can cooperatives create enough collective scale to give independent pharmacies some of the economic leverage enjoyed by vertically integrated competitors?
SEGMENT 3
David A. Hargraves — CEO, Pharma Logistics
Jessica Daley — Industry Intelligence
Pharmacy Supply Chain: Fighting for Every Dollar
Finally, we turn to an issue that doesn't always generate headlines but directly affects pharmacy profitability:
What happens to medication inventory after a pharmacy can no longer use it?
Pharmacies continue to face significant economic pressure, and many of the largest forces affecting reimbursement remain outside the direct control of the pharmacy owner.
But there are areas pharmacies — and policymakers — can change.
One is pharmaceutical return policy.
The Problem
Pharmacy economics are being squeezed from multiple directions.
Reimbursement pressure.
Inventory expense.
Expired medication.
Operational costs.
Supply-chain complexity.
When margins are razor thin, seemingly small inefficiencies become substantial.
The Opportunity
Medication return policies represent an area where pharmacies may have an opportunity to recover value that otherwise disappears from the business.
Virginia's regulations, for example, specifically address circumstances under which drugs can be returned within the supply chain while maintaining appropriate storage conditions, documentation and product integrity.
The Bigger Conversation
With David A. Hargraves, CEO of Pharma Logistics, and Jessica Daley of Industry Intelligence, we examine how smarter pharmaceutical returns and responsible policy reform could improve pharmacy economics.
Closing Thought
As we head into NCPA 2026, the independent pharmacy conversation isn't simply about surviving another difficult year.
It's about finding leverage.
Leverage through AI.
Leverage through cooperative scale.
Leverage through better supply-chain economics.
And leverage through policy change.
Independent pharmacy may not control every economic force affecting the profession — but this week's TWIRx demonstrates that there are still areas where pharmacy owners, innovators and advocates can take action.
We'll see you in Kansas City for NCPA 2026.
